Mounjaro

News

Lilly trims sales forecast on weaker obesity/diabetes growth

Eli Lilly has revised its revenue forecast for 2024 after seeing weaker-than-expected growth for its diabetes and obesity therapies.

News

Lilly Kenosha County - Expansion Rendering

Lilly invests another $3bn in its manufacturing network

Lilly will spend $3 billion on a recently acquired Wisconsin plant for injectable medicines, including diabetes and obesity drugs.

News

Mounjaro cleared for NHS use, but patients may have to wait

Many patients can expect a long wait for access to Eli Lilly's obesity shot Mounjaro, even though it has been recommended for routine NHS use by NICE

News

FDA rethinking block on compounding of Lilly's obesity drug

The FDA has said it has agreed to reconsider its decision to prevent compounding pharmacies from producing and selling versions of Eli Lilly's diabetes and obesity drug tirzepatide.

News

Mounjaro and Zepbound shortages over, declares FDA

The US Food and Drug Administration (FDA) has declared an end to the shortage of tirzepatide, the active ingredient in

News

Lilly says tirzepatide staves off diabetes in phase 3 trial

Eli Lilly's latest clinical readout for dual GIP/GLP-1 agonist tirzepatide is a big one, with data suggesting the drug can reduce the risk of developing type 2 diabetes in overweight and ob

Lilly trims sales forecast on weaker obesity/diabetes growth

Lilly invests another $3bn in its manufacturing network

Mounjaro cleared for NHS use, but patients may have to wait

FDA rethinking block on compounding of Lilly's obesity drug

Mounjaro and Zepbound shortages over, declares FDA

Lilly says tirzepatide staves off diabetes in phase 3 trial

ASCO 2026: All about DNA damage response, with Luke Piggot

Discover a new era of healthcare panel engagement: Grounded ...

Mounjaro

Editor's Picks